

Shahneen Sandhu Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6539804/publications.pdf>

Version: 2024-02-01

131
papers

16,795
citations

38660

50
h-index

16127

124
g-index

132
all docs

132
docs citations

132
times ranked

19029
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	13.9	1,796
2	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
3	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	13.9	1,327
4	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
5	[¹⁷⁷ Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 825-833.	5.1	823
6	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 368-376.	0.6	641
7	[¹⁷⁷ Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet</i> , The, 2021, 397, 797-804.	6.3	552
8	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2013, 14, 882-892.	5.1	497
9	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	5.1	450
10	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019, 36, 385-401.e8.	7.7	359
11	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
12	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	7.7	341
13	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). <i>Annals of Oncology</i> , 2013, 24, 1807-1812.	0.6	310
14	Secondary mutations in <i>BRCA2</i> associated with clinical resistance to a PARP inhibitor. <i>Journal of Pathology</i> , 2013, 229, 422-429.	2.1	287
15	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
16	Dosimetry of ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 517-523.	2.8	285
17	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.4	270
18	Envisioning the future of early anticancer drug development. <i>Nature Reviews Cancer</i> , 2010, 10, 514-523.	12.8	262

#	ARTICLE	IF	CITATIONS
19	Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090.	6.3	240
20	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , 2012, 23, 2943-2947.	0.6	224
21	A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1041-1050.	1.1	216
22	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	9.4	198
23	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 857-865.	2.8	191
24	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 510-520.	5.1	183
25	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 1743-1751.	3.9	180
26	Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 31-49.	157.7	178
27	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for ¹⁷⁷ Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2019, 2, 670-676.	2.6	134
28	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	3.2	126
29	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. <i>Lancet Oncology, The</i> , 2012, 13, 1114-1124.	5.1	125
30	Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 302-306.	12.5	120
31	Nomograms to predict outcomes after ¹⁷⁷ Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology, The</i> , 2021, 22, 1115-1125.	5.1	120
32	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. <i>Annals of Oncology</i> , 2019, 30, 804-814.	0.6	117
33	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective. <i>European Journal of Cancer</i> , 2010, 46, 9-20.	1.3	108
34	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [¹⁷⁷ Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2322-2327.	3.3	101
35	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , 2018, 73, 687-693.	0.9	99
36	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. <i>European Urology</i> , 2013, 64, 300-306.	0.9	85

#	ARTICLE	IF	CITATIONS
37	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , 2017, 283, 168-177.	3.6	81
38	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	0.9	80
39	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. , 2020, 8, e000453.		80
40	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 504-508.	0.6	70
41	Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinomaâ€”The RAPPORT Trial. <i>European Urology</i> , 2022, 81, 364-372.	0.9	70
42	Genome-wide plasma DNA methylation features of metastatic prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1991-2000.	3.9	68
43	Cell cycle control as a promising target in melanoma. <i>Current Opinion in Oncology</i> , 2015, 27, 141-150.	1.1	67
44	A community-based model of rapid autopsy in end-stage cancer patients. <i>Nature Biotechnology</i> , 2016, 34, 1010-1014.	9.4	66
45	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
46	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 1416-1418.	0.6	62
47	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ†. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	0.6	62
48	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 37-47.	1.9	60
49	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5539-5552.	3.2	59
50	Prostate cancer cellâ€”intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. <i>EMBO Reports</i> , 2020, 21, e50162.	2.0	58
51	Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program. , 2020, 8, e000313.		54
52	The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, 1174-1177.	0.6	53
53	Rheumatic immune-related adverse events secondary to antiâ€”programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. <i>European Journal of Cancer</i> , 2018, 105, 88-102.	1.3	53
54	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016, 61, 111-121.	1.3	51

#	ARTICLE	IF	CITATIONS
55	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	51
56	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 4064-4071.	3.2	50
57	A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2016, 114, 889-896.	2.9	46
58	High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot. , 2020, 8, e000792.		45
59	TheraP: ¹⁷⁷ Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5000-5000.	0.8	44
60	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786.	3.3	42
61	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , 2021, 147, 74-83.	1.3	42
62	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). <i>Clinical Cancer Research</i> , 2022, 28, 1518-1530.	3.2	41
63	Prostate-specific membrane antigen theranostics. <i>Current Opinion in Urology</i> , 2018, 28, 197-204.	0.9	39
64	Efficacy and Safety of ¹⁷⁷ Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	0.9	39
65	PARP Inhibitors. <i>Drugs</i> , 2012, 72, 1579-1590.	4.9	36
66	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	3.2	36
67	Mortality due to immunotherapy related hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 976-978.	1.8	34
68	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. <i>Cell Reports</i> , 2021, 34, 108585.	2.9	33
69	The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology. <i>Nature Communications</i> , 2021, 12, 5049.	5.8	33
70	The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment. <i>Current Drug Targets</i> , 2011, 12, 2034-2044.	1.0	32
71	Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. <i>British Journal of Cancer</i> , 2012, 106, 1728-1734.	2.9	31
72	The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. <i>Journal of Cancer Survivorship</i> , 2019, 13, 503-511.	1.5	31

#	ARTICLE	IF	CITATIONS
73	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24.	1.3	31
74	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy. <i>European Urology Focus</i> , 2021, 7, 234-237.	1.6	31
75	HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine. <i>Current Drug Targets</i> , 2011, 12, 2045-2058.	1.0	30
76	Recent Insights and Advances in the Management of Merkel Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 637-646.	2.5	30
77	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , 2017, 23, 6070-6077.	3.2	30
78	Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. , 2021, 9, e002121.		30
79	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. <i>SLAS Discovery</i> , 2021, 26, 1107-1124.	1.4	30
80	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. <i>Clinical Cancer Research</i> , 2011, 17, 5188-5196.	3.2	29
81	Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1020-1027.	1.0	29
82	Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. <i>Health Science Reports</i> , 2019, 2, e115.	0.6	29
83	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846.	0.8	29
84	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5004-LBA5004.	0.8	29
85	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	0.9	28
86	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). <i>Melanoma Research</i> , 2020, 30, 261-267.	0.6	27
87	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. <i>European Urology Focus</i> , 2022, 8, 1157-1168.	1.6	26
88	E6AP promotes prostate cancer by reducing p27 expression. <i>Oncotarget</i> , 2017, 8, 42939-42948.	0.8	25
89	18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors. <i>PET Clinics</i> , 2020, 15, 11-22.	1.5	22
90	Î³ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. <i>Cancer Immunology Research</i> , 2021, 9, 612-623.	1.6	22

#	ARTICLE	IF	CITATIONS
91	Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. <i>Neoplasia</i> , 2019, 21, 389-400.	2.3	20
92	Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175.	1.1	20
93	The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9605-TPS9605.	0.8	19
94	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1079-1084.	2.9	18
95	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 418-426.	1.2	18
96	Efficacy of immune checkpoint inhibitors for in-transit melanoma. , 2020, 8, e000440.		18
97	ENZA trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). <i>BJU International</i> , 2021, 128, 642-651.	1.3	18
98	Relevance of DNA damage repair in the management of prostate cancer. <i>Current Problems in Cancer</i> , 2017, 41, 287-301.	1.0	16
99	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	1.2	16
100	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e200-e205.	0.9	16
101	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. <i>Cancer Cell</i> , 2011, 19, 573-574.	7.7	15
102	Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma. <i>Investigational New Drugs</i> , 2020, 38, 844-854.	1.2	15
103	PRINCE: Phase I trial of ¹⁷⁷ Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5017-5017.	0.8	15
104	The changing paradigm of managing Merkel cell carcinoma in Australia: An expert commentary. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 312-319.	0.7	13
105	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the "Australian guidelines for the management of cutaneous melanoma"™. <i>Australasian Journal of Dermatology</i> , 2017, 58, 274-277.	0.4	12
106	Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. <i>Prostate</i> , 2019, 79, 1326-1337.	1.2	12
107	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. <i>European Journal of Cancer</i> , 2021, 151, 72-83.	1.3	12
108	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. <i>IScience</i> , 2019, 22, 1-15.	1.9	11

#	ARTICLE	IF	CITATIONS
109	Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study. <i>Quality of Life Research</i> , 2020, 29, 2021-2027.	1.5	11
110	Integration of Immuno-Oncology and Palliative Care. <i>Journal of Clinical Oncology</i> , 2016, 34, 1561-1562.	0.8	10
111	[¹⁷⁷ Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply. <i>Lancet Oncology</i> , The, 2018, 19, e373.	5.1	10
112	Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. <i>BMC Medical Genomics</i> , 2019, 12, 115.	0.7	10
113	The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer. <i>European Urology</i> , 2017, 71, 748-749.	0.9	9
114	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , 2021, 13, 2334.	1.7	9
115	CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2140-2150.	1.9	9
116	Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. <i>European Urology</i> , 2019, 75, 927-928.	0.9	8
117	Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma. , 2020, 8, e000700.		8
118	i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol. <i>BMJ Open</i> , 2020, 10, e036059.	0.8	8
119	Microbiome transplantation and modulation of immune related adverse events. <i>EClinicalMedicine</i> , 2019, 8, 10-11.	3.2	7
120	Characterization of the treatment-naïve immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
121	Use of vemurafenib in a patient unable to swallow whole. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 733-737.	0.5	6
122	Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. , 2022, 10, e004574.		6
123	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. <i>Investigational New Drugs</i> , 2022, 40, 1051-1065.	1.2	4
124	Toward a Better Dialogue Between Neuro-Oncologists and Phase I Investigators. <i>Journal of Clinical Oncology</i> , 2012, 30, 562-563.	0.8	3
125	DETECTION phase II/III trial: Circulating tumor DNA-guided therapy for stage IIB/C melanoma after surgical resection.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9603-TPS9603.	0.8	3
126	Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection. <i>European Urology</i> , 2017, 71, 883-885.	0.9	2

#	ARTICLE	IF	CITATIONS
127	Reply to M. Horiguchi et al. Journal of Clinical Oncology, 2018, 36, 722-723.	0.8	2
128	Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. Prostate, 2022, 82, 993-1002.	1.2	2
129	Reply: "Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer". British Journal of Cancer, 2014, 110, 267-268.	2.9	1
130	Reply to E. Hindi. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
131	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷ Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5027-5027.	0.8	1